AMF 26Alternative Names: 2-methylcoprophilinamide; AMF-26; M-COPA
Latest Information Update: 15 Feb 2017
At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics; Pyridines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Type-2 fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Feb 2017 Chemical structure information added